Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Growth Hormone for Gastroparesis
NCT06803589Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of somapacitan in gastroparesis, sponsored by Mayo Clinic. Primary endpoint: Gastroparesis Cardinal Symptom Index at 14 weeks. Started Oct 2024; status: recruiting.
02
Drugs
somapacitan
03
Conditions
gastroparesis
Beyond the preview
Go deeper on NCT06803589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06803589.